Log in to save to my catalogue

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9691220

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

About this item

Full title

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Publisher

Switzerland: MDPI AG

Journal title

Genes, 2022-11, Vol.13 (11), p.2065

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is overexpressed in 20-30% of breast cancers and is associated with poor prognosis and worse overall patient survival. Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies. The development of HER2-directed therapeutics is an...

Alternative Titles

Full title

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9691220

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9691220

Other Identifiers

ISSN

2073-4425

E-ISSN

2073-4425

DOI

10.3390/genes13112065

How to access this item